Last reviewed · How we verify
NCT06358586
New Paediatric Formulation of Tachipirina®
NA trial testing Tachipirina® 120 mg/5 mL oral suspension, new flavour in Healthy in 20 participants. Completed in 25 April 2022.
25 April 2022
Quick facts
| Lead sponsor | Aziende Chimiche Riunite Angelini Francesco S.p.A |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 20 |
| Start date | 9 April 2022 |
| Primary completion | 25 April 2022 |
| Estimated completion | 25 April 2022 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Tachipirina® 120 mg/5 mL oral suspension, new flavour — full drug profile →
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Aziende Chimiche Riunite Angelini Francesco S.p.A — full company profile →
Who can join
Adults 6 to 17, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single centre, single dose, single-arm, open-label, palatability study. The aim of the present study is to investigate the palatability of the newly developed Tachipirina® 120 mg/5 mL oral suspension with strawberry flavour. The study will be conducted in paediatric volunteers that represent the target population for this product.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06358586
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Aziende Chimiche Riunite Angelini Francesco S.p.A trials
Trials by the same sponsor.
- NCT07199543 — Palatability Study of Five Formulations of Benzydamine HCl Lozenges · Phase 1 · completed
- NCT06922175 — REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization · recruiting
- NCT06650631 — The Effectiveness of Heat Treatment on Knee Pain in Patients With Osteoarthritis - an International, Multicenter Clinica · NA · recruiting
- NCT06773767 — Bioavailability of Trazodone Hydrochloride (New Polymer) vs. Trazodone Hydrochloride Contramid® at Steady-state. · Phase 1 · completed
- NCT05867160 — Adjunctive Anti-seizure Medication (ASM) Real World Evidence (RWE) Study · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06358586 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aziende Chimiche Riunite Angelini Francesco S.p.A
- Last refreshed: 10 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06358586.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing